Filing Flows › AbbVie (ABBV) › Q3 2026 › vs Q2 2026
AbbVie (ABBV) Q3 2026 vs Q2 2026 (quarter over quarter)
AbbVie's revenue rose $414M (+2%) from $17.0B in Q2 2026 to $17.4B in Q3 2026. Operating margin 36.0% against 37.9% (-1.8 pts).
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 36.0% | 37.9% | -1.8 pts |
| Net margin | 24.2% | 21.3% | +3.0 pts |
| Free cash flow margin | 42.0% | 18.3% | +23.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $17.4B | $17.0B | $414M | +2% |
| Operating profit | $6.3B | $6.4B | −$165M | -3% |
| Costs & expenses | $11.1B | $10.6B | $579M | +5% |
| Pre-tax earnings | $4.8B | $4.3B | $551M | +13% |
| Other expense, net | $1.4B | $2.2B | −$716M | -33% |
| Cost of revenue | $4.3B | $4.3B | −$6.0M | -0.1% |
| Research & development | $2.6B | $2.3B | $223M | +10% |
| SG&A | $4.1B | $3.6B | $455M | +13% |
| Other operating costs | $198M | $291M | −$93.0M | -32% |
| Net earnings | $4.2B | $3.6B | $604M | +17% |
| Income tax | $609M | $662M | −$53.0M | -8% |
| Depreciation & amortization | $1.9B | $1.9B | −$2.0M | -0.1% |
| Share-based compensation | $160M | $166M | −$6.0M | -4% |
| Working capital & other | $1.3B | −$2.2B | $3.6B | — |
| Operating cash flow | $7.6B | $3.4B | $4.2B | +121% |
| Free cash flow (OCF − capex) | $7.3B | $3.1B | $4.2B | +135% |
| Capital expenditures | $301M | $322M | −$21.0M | -7% |
Questions
How much did AbbVie's revenue grow quarter over quarter in Q3 2026?
AbbVie's revenue rose $414M (+2%) from $17.0B in Q2 2026 to $17.4B in Q3 2026. Operating margin 36.0% against 37.9% (-1.8 pts).